114 related articles for article (PubMed ID: 12648572)
21. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
22. Establishment and characterization of two cell lines (HEC-155, HEC-180) derived from uterine papillary serous adenocarcinoma.
Iida T; Hamano M; Yoshida N; Yonamine K; Hayashi K; Kiguchi K; Ishizuka B; Nishimura Y; Arai T; Kawaguchi M; Hata H; Watanabe J; Kuramoto H
Eur J Gynaecol Oncol; 2004; 25(4):423-7. PubMed ID: 15285295
[TBL] [Abstract][Full Text] [Related]
23. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Schwab CL; English DP; Roque DM; Bellone S; Lopez S; Cocco E; Nicoletti R; Rutherford TJ; Schwartz PE; Santin AD
Gynecol Oncol; 2014 Oct; 135(1):142-8. PubMed ID: 25124161
[TBL] [Abstract][Full Text] [Related]
24. Uterine papillary serous carcinoma: what have we learned over the past quarter century?
Goff BA
Gynecol Oncol; 2005 Sep; 98(3):341-3. PubMed ID: 16111527
[No Abstract] [Full Text] [Related]
25. Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.
Zhu L; Lopez S; Bellone S; Black J; Cocco E; Zigras T; Predolini F; Bonazzoli E; Bussi B; Stuhmer Z; Schwab CL; English DP; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
Tumour Biol; 2015 Jul; 36(7):5505-13. PubMed ID: 25669172
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of Her-2/neu overexpression in uterine serous carcinoma.
Díaz-Montes TP; Ji H; Smith Sehdev AE; Zahurak ML; Kurman RJ; Armstrong DK; Bristow RE
Gynecol Oncol; 2006 Jan; 100(1):139-44. PubMed ID: 16182348
[TBL] [Abstract][Full Text] [Related]
27. Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma.
Mahdi H; Xiu J; Reddy SK; DeBernardo R
J Surg Oncol; 2015 Aug; 112(2):188-94. PubMed ID: 26250968
[TBL] [Abstract][Full Text] [Related]
28. Re: Uterine papillary serous carcinoma: patterns of metastatic spread.
Thomas GM
Gynecol Oncol; 1995 Jun; 57(3):437-8. PubMed ID: 7774855
[No Abstract] [Full Text] [Related]
29. [Uterine papillary serous carcinoma].
Kedzia H; Spaczyński M
Ginekol Pol; 1994 Oct; 65(10):587-92. PubMed ID: 7729721
[TBL] [Abstract][Full Text] [Related]
30. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
[TBL] [Abstract][Full Text] [Related]
31. Uterine papillary serous carcinoma: a new paradigm for treatment?
Annunziata CM; Kotz HL
Cancer; 2009 Aug; 115(16):3594-6. PubMed ID: 19452535
[No Abstract] [Full Text] [Related]
32. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor.
English DP; Roque DM; Carrara L; Lopez S; Bellone S; Cocco E; Bortolomai I; Schwartz PE; Rutherford T; Santin AD
Gynecol Oncol; 2013 Dec; 131(3):753-8. PubMed ID: 24012800
[TBL] [Abstract][Full Text] [Related]
33. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy.
Santin AD; Zhan F; Cane' S; Bellone S; Palmieri M; Thomas M; Burnett A; Roman JJ; Cannon MJ; Shaughnessy J; Pecorelli S
Br J Cancer; 2005 Apr; 92(8):1561-73. PubMed ID: 15785748
[TBL] [Abstract][Full Text] [Related]
34. Papillary serous carcinoma of the uterus arising in an adenomyoma.
Griffin M; Parai S; Ghatage P; Dimakulangan A
Acta Cytol; 1996; 40(4):849-50. PubMed ID: 8693916
[No Abstract] [Full Text] [Related]
35. Metastatic uterine papillary serous carcinoma to the pericardium.
Ramirez PT; Ramondetta LM; Burke TW; Gershenson DM; Brewer MA
Gynecol Oncol; 2001 Oct; 83(1):135-7. PubMed ID: 11585425
[TBL] [Abstract][Full Text] [Related]
36. [Immunohistochemical study of adhesive molecules Her-2/neu in nonendometrial carcinoma of corpus uteri].
abdulaeva GM; Anurova OA; Laktionov KP; Gadzhieva SM
Arkh Patol; 2012; 74(1):12-5. PubMed ID: 22712297
[TBL] [Abstract][Full Text] [Related]
37. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma.
Schmitz MJ; Hendricks DT; Farley J; Taylor RR; Geradts J; Rose GS; Birrer MJ
Gynecol Oncol; 2000 Jun; 77(3):439-45. PubMed ID: 10831356
[TBL] [Abstract][Full Text] [Related]
38. Uterine papillary serous carcinoma revisited.
Hendrickson MR; Longacre TA; Kempson RL
Gynecol Oncol; 1994 Sep; 54(3):261-3. PubMed ID: 8088601
[No Abstract] [Full Text] [Related]
39. Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation.
Singh P; Smith CL; Cheetham G; Dodd TJ; Davy ML
Int J Gynecol Cancer; 2008; 18(6):1344-51. PubMed ID: 18248390
[TBL] [Abstract][Full Text] [Related]
40. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
